PBAC's latest decision on Leuprorelin and bicalutamide: Recommended (2016). Considered for Treatment of metastatic (Stage D) carcinoma of the prostate. Patients must require a combination of an antiandrogen and a GnRH (LH-RH) agonist.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Adults with metastatic (Stage D) carcinoma of the prostate requiring combination antiandrogen and GnRH agonist therapy.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
co-prescribed leuprorelin and bicalutamide (primary); goserelin and bicalutamide combination pack (secondary)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis. No ICER calculated; submission based on price comparison of combination pack versus individual components.